```
     FILE 'REGISTRY' ENTERED AT 13:08:16 ON 30 APR 2010
                EXP GANGLIOSIDE GD3
                EXP GANGLIOSIDE GD3/CN
L1             2 S E3

     FILE 'HCAPLUS' ENTERED AT 13:08:49 ON 30 APR 2010
L2           121 S L1/THU
L3        390905 S INFLAMM? OR ANTIINFLAMM?
L4            20 S L2 AND L3
L5        265180 S CHOLESTEROL OR HYPERCHOLESTEROLEM? OR ATHEROSCLEROSIS
L6             8 S L2 AND L5
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 13:08:16 ON 30 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 APR 2010  HIGHEST RN 1220951-91-6
DICTIONARY FILE UPDATES:  29 APR 2010  HIGHEST RN 1220951-91-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp ganglioside GD3
E1            3     GANGLIOSID/BI
E2         1271     GANGLIOSIDE/BI
E3            0 --> GANGLIOSIDE GD3/BI
E4            7     GANGLIOSIDES/BI
E5            1     GANGLIOSIDOL/BI
E6            2     GANGLIOSIDOSIS/BI
E7            1     GANGLIOSPHINGO/BI
E8            1     GANGLIOSPHINGOSINE/BI
E9            1     GANGLIOSTAT/BI
E10           4     GANGLIOTETRA/BI
E11           1     GANGLIOTETRAOSE/BI
E12           3     GANGLIOTETRAOSYL/BI

=> exp ganglioside GD3/cn
E1            1     GANGLIOSIDE GD2, N'-ACETYL-N-GLYCOLOYL-/CN
E2            1     GANGLIOSIDE GD2, N,N'-DIACETYL-/CN
E3            2 --> GANGLIOSIDE GD3/CN
E4            1     GANGLIOSIDE GD3 (SYNTHETIC)/CN
E5            1     GANGLIOSIDE GD3 B1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE/
                    CN
E6            1     GANGLIOSIDE GD3 ACETYLGALACTOSAMINYLTRANSFERASE/CN
E7            1     GANGLIOSIDE GD3 AMIDE/CN
E8            1     GANGLIOSIDE GD3 LACTONE I/CN
E9            1     GANGLIOSIDE GD3 LACTONE II/CN
E10           1     GANGLIOSIDE GD3 SYNTHASE/CN
E11           1     GANGLIOSIDE GD3 SYNTHASE (HUMAN CLONE PAMO-GD3)/CN
E12           1     GANGLIOSIDE GD3 SYNTHETASE/CN

=> s e3
L1            2 "GANGLIOSIDE GD3"/CN
```

=> d l1 scan

L1 2 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Ceramide, 1-O-[O-(N-acetyl-α-neuraminosyl)-(2→8)-O-(N-acetyl-
    α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-
    (1→4)-β-D-glucopyranosyl]-
MF Unspecified
CI COM, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L1 2 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN Ganglioside GD3
MF Unspecified
CI COM, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file hcaplus
COST IN U.S. DOLLARS   SINCE FILE ENTRY   TOTAL SESSION
FULL ESTIMATED COST   5.99   6.21

FILE 'HCAPLUS' ENTERED AT 13:08:49 ON 30 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Apr 2010 VOL 152 ISS 19
FILE LAST UPDATED: 29 Apr 2010 (20100429/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l1/thu
          1576 L1
       1237249 THU/RL
L2         121 L1/THU
                (L1 (L) THU/RL)

=> s inflamm? or antiinflamm?
        381286 INFLAMM?
         66629 ANTIINFLAMM?
L3      390905 INFLAMM? OR ANTIINFLAMM?

=> s l2 and l3
L4          20 L2 AND L3

=> d l4 1-20 ti abs bib

L4   ANSWER 1 OF 20  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Anti-glucan antibody recruitment of complement-mediated immune responses
AB   The authors disclose the presence of human natural antibodies to
     β1-6-glucans.  In one example, anti-β1-6 glucan IgG antibodies
     are shown to mediate complement activation and neutrophil phagocytosis.
     In a second example, a conjugate of Herceptin with β1-6 glucan was
     shown to target breast cancer cells for complement-mediated lysis and
     recruitment of neutrophils.
AN   2009:1366143  HCAPLUS <<LOGINID::20100430>>
DN   151:526825
TI   Anti-glucan antibody recruitment of complement-mediated immune responses
IN   Rubin-Bejerano, Ifat; Fink, Gerald R.; Kohane, Daniel S.
PA   Immunexcite, Inc., USA
SO   PCT Int. Appl., 74 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2009134891        A2    20091105    WO 2009-US42117        20090429
     WO 2009134891        A3    20100218
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRAI US 2008-71437P       P     20080429

L4   ANSWER 2 OF 20  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Compositions comprising phospholipids
AB   The present invention provides compns. comprising phospholipids and
     particularly those comprising at least 40% phospholipid and at least 80%
```

phospholipid as a percentage of total fat in the extract, comprising polyunsatd. and saturated phospholipids, in a ratio of saturated phospholipid to monounsatd. to polyunsatd. phospholipid of about 6:3:1 resp., or comprising at least 40% phospholipid and less than 40% protein and methods for their production from dairy products.

AN 2009:239236 HCAPLUS <<LOGINID::20100430>>

DN 150:258888

TI Compositions comprising phospholipids

IN Brown, Andrew; Rowney, Michelle

PA Murray Goulburn Co-Operative Co. Limited, Australia

SO PCT Int. Appl., 80pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009023903	A1	20090226	WO 2008-AU1191	20080815
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2008288677	A1	20090226	AU 2008-288677	20080815
	EP 2178539	A1	20100428	EP 2008-782939	20080815
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				
PRAI	AU 2007-904444	A	20070817		
	WO 2008-AU1191	W	20080815		

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Method and apparatus of low strength electric field network-mediated delivery of drug, gene, siRNA, shRNA, protein, peptide, antibody or other biomedical and therapeutic molecules and reagents in skin, soft tissue, joints and bone

AB The invention includes four preferred embodiments: (i) a method and apparatus for the joint and its related soft tissue for bone gene, protein and drug delivery; (ii) a method and apparatus for gene, protein and drug delivery to an extremity; (iii) a method and apparatus for delivery of gene, protein and drug delivery to skin and soft tissue; and/or (iv) a method and apparatus for delivery of a gene, protein and drug to soft tissue tumor. The apparatus for transfecting drug, gene, siRNA, shRNA, protein, peptide, antibody or other biomedical and therapeutic mols. and reagents comprises a plurality of neg. electrodes disposed into low resistance elec. contact with skin overlaying the tissue.

AN 2007:1207931 HCAPLUS <<LOGINID::20100430>>

DN 147:474740

TI Method and apparatus of low strength electric field network-mediated delivery of drug, gene, siRNA, shRNA, protein, peptide, antibody or other biomedical and therapeutic molecules and reagents in skin, soft tissue,

joints and bone
IN Sen, Luyi
PA The University of California, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007120557	A2	20071025	WO 2007-US8445	20070402
	WO 2007120557	A3	20081113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2647520	A1	20071025	CA 2007-2647520	20070402
	EP 2001519	A2	20081217	EP 2007-774731	20070402
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	CN 101506370	A	20090812	CN 2007-80000069	20070830
	IN 2008CN05422	A	20090320	IN 2008-CN5422	20081010
PRAI	US 2006-744528P	P	20060410		
	US 2006-819277P	P	20060706		
	WO 2007-US8445	W	20070402		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Formulations for mediating inflammatory bowel disorders
AB The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liqs. with gangliosides, for example infant formula or infant foods, can be employed according to the invention.
AN 2007:815148 HCAPLUS <<LOGINID::20100430>>
DN 147:197354
TI Formulations for mediating inflammatory bowel disorders
IN Clandinin, Michael Thomas; Park, Eek J.
PA Mti Meta Tech Inc., Can.
SO U.S. Pat. Appl. Publ., 39pp., Cont.-in-part of U.S. Ser. No. 551,789
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 20070173480 A1 20070726 US 2007-622858 20070112
WO 2004087173 A2 20041014 WO 2004-CA375 20040312
WO 2004087173 A3 20041125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 20060276430 A1 20061207 US 2004-551789 20040312
PRAI US 2004-551789 A2 20040312
WO 2004-CA375 W 20040312
US 2003-404095 A 20030402
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L4 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Gangliosides as binding agents for vacuolating toxin VacA of Helicobacter pylori, their use for drugs and for foods, and screening method for therapeutic or prophylactic drugs for H. pylori-related diseases
AB The binding agents for VacA, vacuolating toxin of H. pylori, contain gangliosides, lysogangliosides, and/or their chemical modification products. VacA activity is neutralized by the VacA-binding agents for treatment or prevention of H. pylori-related diseases, e.g., gastritis, gastric ulcer, and gastric cancer. The VacA-binding agents or VacA are used for screening of therapeutic or prophylactic drugs for H. pylori-related diseases. Gangliosides, lysogangliosides, and/or their chemical modification products are used for manufacture of therapeutic or prophylactic drugs for H. pylori-related diseases and for foods for suppression of the actions of H. pylori. Ganglioside GM1 (at 50 μg/mL) significantly inhibited the vacuolating activity of VacA in cultured human gastric epithelial cancer cell line AZ-521.
AN 2007:251881 HCAPLUS <<LOGINID::20100430>>
DN 146:266771
TI Gangliosides as binding agents for vacuolating toxin VacA of Helicobacter pylori, their use for drugs and for foods, and screening method for therapeutic or prophylactic drugs for H. pylori-related diseases
IN Wada, Akihiro; Hirayama, Toshiya; Yamazaki, Shigeki; Maeda, Kayo; Hasegawa, Makoto
PA Nagasaki University, Japan; Kansai Bunri Sougougakuen
SO Jpn. Kokai Tokkyo Koho, 14pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2007055921	A	20070308	JP 2005-241839	20050823
PRAI JP 2005-241839		20050823		

L4 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine
AB As a result of its metastatic potential, canine malignant melanoma like its human counterpart like its human counter part, has a poor response to conventional treatment protocols. This prompted us to investigate the possibility of enhancing the immune response against the melanoma cell

surface antigen, disialoganglioside GD3. Initially a flow cytometric study was designed in which the incidence of GD3 on the cell surface, recognized by the monoclonal antibody Mel-1 (R24), was established in canine melanoma cell lines. Results from the flow cytometry found GD3 to be highly expressed (94.2%) in six out of seven canine melanoma cell lines. Since it was thus potentially a good target, a study in which normal dogs were vaccinated intradermally with a vaccine containing GD3 plus adjuvants was designed. The adjuvant included CpG oligodeoxynucleotide (CpG-ODN) sequences and RIBI-adjuvant, which are known to target toll-like receptors (TLR) of the innate immune system. From a cohort of 10 dogs, 4 were vaccinated 3 times, at 4 weekly intervals with GD3 plus adjuvant, and 4 received only RIBI-adjuvant, and 2 phosphate buffered saline. Caliper measurements were collected to assess skin reaction at the vaccination site and sera assayed for IgM and IgG antibodies against GD3 and cell-mediated cytotoxicity against a melanoma cell line. Results from the study found significant differences ($P < 0.05$) in the vaccine site reactions, IgM/IgG levels and cell-mediated cytotoxicity in the vaccinated vs. unvaccinated dogs. The addition of CpG-ODN sequences and increasing GD3 concentration in the vaccine increased the inflammation response at the injection site. GD3 IgG and IgM antibodies in vaccinated dogs showed increasing titers over time and achieved significance at weeks 9 and 12, resp. Cell-mediated cytotoxicity was only detected in peripheral blood mononuclear cells from vaccinated dogs. In conclusion, by combining the tumor antigen GD3 (a known weak self-antigen) and an adjuvant, tolerance was overcome by an innate and adaptive immune response in this population of normal dogs.

AN 2006:1139866 HCAPLUS <<LOGINID::20100430>>
DN 146:226964
TI The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine
AU Milner, R. J.; Salute, M.; Crawford, C.; Abbot, J. R.; Farese, J.
CS Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
SO Veterinary Immunology and Immunopathology (2006), 114(3-4), 273-284
CODEN: VIIMDS; ISSN: 0165-2427
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Bispecific antibodies, chimeric antibodies and fragments specific to human CD3 complex and antigen or tumor antigen for diagnosis and treatment of cancer, inflammation, allergy, infection and autoimmune disease
AB The present invention provides a bispecific binding mol., wherein said mol. comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid mols. encoding the bispecific binding mols. of the invention, vectors comprising said nucleic acid mols. and host cells transformed or transfected with said vectors. Moreover, the invention concerns a method for the production of bispecific binding mols. of the invention and compns. comprising the bispecific binding mols. of the invention, the nucleic acid mols. of the invention or the host cells of the invention.
AN 2005:902921 HCAPLUS <<LOGINID::20100430>>

DN 143:246762
TI Bispecific antibodies, chimeric antibodies and fragments specific to human CD3 complex and antigen or tumor antigen for diagnosis and treatment of cancer, inflammation, allergy, infection and autoimmune disease
IN Kufer, Peter; Lenkkeri-Schuetz, Ulla; Lutterbuese, Ralf; Kohleisen, Birgit
PA Micromet A.-G., Germany
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005077982	A1	20050825	WO 2005-EP1573	20050216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005212830	A1	20050825	AU 2005-212830	20050216
	CA 2555503	A1	20050825	CA 2005-2555503	20050216
	EP 1716178	A1	20061102	EP 2005-715354	20050216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
	CN 1950399	A	20070418	CN 2005-80008594	20050216
	BR 2005007649	A	20070710	BR 2005-7649	20050216
	ZA 2006006410	A	20071227	ZA 2006-6410	20050216
	JP 2008506353	T	20080306	JP 2006-552576	20050216
	IN 2006CN02984	A	20070608	IN 2006-CN2984	20060814
	MX 2006009253	A	20070418	MX 2006-9253	20060815
	NO 2006004183	A	20061108	NO 2006-4183	20060915
	KR 2006131892	A	20061220	KR 2006-718976	20060915
	US 20080213256	A1	20080904	US 2008-588734	20080424
PRAI	EP 2004-3445	A	20040216		
	EP 2005-715354	A	20050216		
	WO 2005-EP1573	W	20050216		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Cloning and sequences of genetically engineered proteases that cleave target molecules for diagnosis or treatment of human diseases
AB The present invention provides a disease treatment method by applying a medicament comprising a protease with defined target substrate specificity that enables hydrolysis of specific peptide bonds within the substrate related to such disease. This invention aims to create mutated proteases that target proteins or enzymes associated with disease (several dozen claimed mols.), for the purpose of hydrolysis-mediated alteration of cellular behavior aiding in diagnosis or treatment of human diseases. Specificity determining regions (SDR) from selected proteases were randomly inserted into a protein scaffold, enabling the protein scaffold to perform hydrolysis upon the SDR-determined substrate. Claimed are the sequences of human trypsin I, Bacillus subtilis subtilisin E, human pepsin A, and human

caspase-7. Use of the modified trypsin protease upon tumor necrosis factor-α, serum proteins and VEGF, as well as anal. of corresponding cytotoxicity, is presented. The proteases with such a defined specificity can further be used for related therapeutic or diagnostic purposes.

AN 2005:735080 HCAPLUS <<LOGINID::20100430>>

DN 143:206400

TI Cloning and sequences of genetically engineered proteases that cleave target molecules for diagnosis or treatment of human diseases

IN Haupts, Ulrich; Koltermann, Andre; Scheidig, Andreas; Votsmeier, Christian; Kettling, Ulrich; Coco, Wayne Michael

PA Germany

SO U.S. Pat. Appl. Publ., 217 pp., Cont.-in-part of U.S. Ser. No. 872,198.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050175581	A1	20050811	US 2004-21951	20041222
	EP 1531179	A1	20050518	EP 2003-25871	20031111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004249903	A1	20041229	AU 2004-249903	20040618
	AU 2004249903	B2	20090604		
	AU 2004249904	A1	20041229	AU 2004-249904	20040618
	CA 2529589	A1	20041229	CA 2004-2529589	20040618
	CA 2529659	A1	20041229	CA 2004-2529659	20040618
	WO 2004113521	A1	20041229	WO 2004-EP51172	20040618
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2004113522	A1	20041229	WO 2004-EP51173	20040618
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050002897	A1	20050106	US 2004-872198	20040618
	EP 1633865	A1	20060315	EP 2004-741841	20040618
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	EP 1633866	A1	20060315	EP 2004-741842	20040618
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006527590	T	20061207	JP 2006-516170	20040618
	JP 2006527738	T	20061207	JP 2006-516171	20040618
PRAI	EP 2003-13819	A	20030618		

	EP 2003-25851	A	20031110
	EP 2003-25871	A	20031111
	US 2003-524960P	P	20031125
	EP 2004-3058	A	20040211
	US 2004-543518P	P	20040211
	US 2004-872198	A2	20040618
	WO 2004-EP51172	W	20040618
	WO 2004-EP51173	W	20040618

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Deimmunized fusion proteins comprising CD3-binding domain and Ig binding domain for diagnosis and treatment of cancer, inflammation, infection, (auto)immune disease or allergy

AB The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. The Ig.-derived binding domain comprises an antigen-interaction site with a specificity for mol. such as EpCAM, CCR5, CD19, Her-2, Her-2/neu, Her-3, Her-4, EGFR, PSMA, CEA, MUC-1, MUC2, MUC3, MUC4, MUC5AC, MUC5a, MUC7, βhCG, Lewis Y, CD20, CD33, CD30, GD3, 9-O-acetyl GD3, GM2, Globo H, fucosyl GM1, polySA, GD2, carboanhydrase IX, CD44v6, sonic Hedgehog, Wue-1, etc. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compns. for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.

AN 2005:395357 HCAPLUS <<LOGINID::20100430>>

DN 142:446010

TI Deimmunized fusion proteins comprising CD3-binding domain and Ig binding domain for diagnosis and treatment of cancer, inflammation, infection, (auto)immune disease or allergy

IN Hofmeister, Robert; Kohleisen, Birgit; Lenkkeri-Schuetz, Ulla; Itin, Christian; Baeuerle, Patrick; Carr, Francis J.; Hamilton, Anita A.; Williams, Stephen

PA Micromet A.-G., Germany

SO PCT Int. Appl., 639 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040220	A1	20050506	WO 2004-EP11646	20041015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283850	A1	20050506	AU 2004-283850	20041015
	CA 2542239	A1	20050506	CA 2004-2542239	20041015
	EP 1673398	A1	20060628	EP 2004-790488	20041015

```
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1867586           A     20061122    CN 2004-80030150       20041015
     CN 100453556         C     20090121
     BR 2004015457        A     20061205    BR 2004-15457          20041015
     ZA 2006001699        A     20070530    ZA 2006-1699           20041015
     JP 2007537714        T     20071227    JP 2006-534709         20041015
     NZ 546173            A     20090430    NZ 2004-546173         20041015
     MX 2006004035        A     20060831    MX 2006-4035           20060410
     IN 2006CN01280       A     20070629    IN 2006-CN1280         20060413
     NO 2006002117        A     20060703    NO 2006-2117           20060511
     US 20090022738       A1    20090122    US 2006-572740         20061204
PRAI EP 2003-23581        A     20031016
     WO 2004-EP11646      W     20041015
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 10 OF 20  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Antibodies conjugated with phagocytic marker for enhancing phagocytosis
     against autoimmune disease, infection, cancer and others
AB   The present invention provides a system for enhancing clearance or
     destruction of undesirable cells or noncellular mol. entities by tagging
     such cells or noncellular mol. entities with a marker that targets the
     cells or noncellular mol. entities for phagocytosis (phagocytic marker).
     The target cells can be, for example, endothelial cells, tumor cells,
     leukocytes, or virus-infected cells.  In certain embodiments of the
     invention the tagging is accomplished by administering a composition comprising
     an antibody or ligand linked to the phagocytotic marker, wherein the
     antibody or ligand binds to a cell type specific marker present on or in
     the cell surface of a target cell.  In preferred embodiments of the
     invention, the phagocytic marker comprises phosphatidylserine or a group
     derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative
     of any of these.
AN   2005:182810  HCAPLUS <<LOGINID::20100430>>
DN   142:278750
TI   Antibodies conjugated with phagocytic marker for enhancing phagocytosis
     against autoimmune disease, infection, cancer and others
IN   Francois, Cedric; Olson, Paul; Deschatelets, Pascal; Machiels, Alec
PA   Potentia Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 173 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   WO 2005019429         A2    20050303    WO 2004-US27245        20040823
     WO 2005019429         A3    20060302
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
```

	US 20050113297	A1	20050526	US 2004-923940	20040823
PRAI	US 2003-497086P	P	20030822		
	US 2003-514941P	P	20031028		
	US 2003-523611P	P	20031119		
	US 2003-524126P	P	20031121		
	US 2003-524730P	P	20031124		
	US 2004-547951P	P	20040226		
	WO 2004-US27245	A	20040823		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:278750
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Human molecules or antibodies specific to human CD3 complex for diagnosis and treatment of proliferative, inflammatory, immune, autoimmune, infectious or allergic diseases
AB The present invention provides a method for the preparation of a human binding mol., fragment or derivative thereof which specifically binds to the human CD3 complex. The binding mols. are human, humanized or deimmunized antibodies or fragments; and are selected from a DNA or RNA library by a phage display method. The antibodies may comprise at least one further antigen-interaction-site and/or effector domain selected from EpCAM, CCR5, CD19, EphA2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, MUC1, MUC2, MUC3, MUC4, MUC5, MUC7, βhCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3, etc. These binding mols. or antibodies and fragments are useful for diagnosis and treatment of proliferative disease, tumor, inflammation, immune disease, autoimmune disease, infection, viral infection, allergy, parasitic infection or graft vs. host disease.
AN 2004:1059392 HCAPLUS <<LOGINID::20100430>>
DN 142:36924
TI Human molecules or antibodies specific to human CD3 complex for diagnosis and treatment of proliferative, inflammatory, immune, autoimmune, infectious or allergic diseases
IN Kufer, Peter; Raum, Tobias; Berry, Meera; Kischel, Roman; Mangold, Susanne; Krinner, Eva; Kohleisen, Birgit; Zeman, Steven; Itin, Christian; Baeuerle, Patrick
PA Micromet A.-G., Germany
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004106380	A2	20041209	WO 2004-EP5684	20040526
WO 2004106380	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004242845	A1	20041209	AU 2004-242845	20040526
CA 2523716	A1	20041209	CA 2004-2523716	20040526

EP 1629011 A2 20060301 EP 2004-739377 20040526
EP 1629011 B1 20100113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
AT 455127 T 20100115 AT 2004-739377 20040526
IN 2005CN02915 A 20070914 IN 2005-CN2915 20051108
IN 228203 A1 20090306
PRAI EP 2003-12132 A 20030531
WO 2004-EP5684 W 20040526
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Glycoconjugates with NeuAc-NeuAc-Gal-Glc are more effective at preventing adhesion of Helicobacter pylori to gastric epithelial cells than glycoconjugates with NeuAc-Gal-Glc
AB Helicobacter pylori (H. pylori) adheres to human gastric epithelial cells, eliciting various gastroduodenal diseases. Gangliosides play a critical role in bacterial adhesion to cell surfaces. The present study examined how residues of gangliosides are important for inhibition of adhesion of H. pylori to MKN-45 cells. We measured adhesion or detachment effects of gangliosides on the interaction between MKN-45 cells and H. pylori, as well as interleukin-8 production Among the gangliosides, O-Ac-GD3, GT1b, GD1a, GD1b, GT1a, and GD3 had potent dose dependent inhibitory effects on adhesion of H. pylori to MKN-45 cells, interleukin-8 production, and vacuole formation induced by H. pylori toxin binding to Vero cells. GD3 also accelerated bacterial detachment of MKN-45 cells with adherent H. pylori in a dose dependent manner. Such results strongly suggest that the mechanism involved in the inhibition of H. pylori adhesion is mediated by the variations of the residues of the NeuAc-NeuAc-Gal-Glc chain of gangliosides. NeuAc-NeuAc-Gal-Glc exhibits a more inhibitory effect on adhesion than the NeuAc-Gal-Glc chain. Such ganglioside and oligosaccharide sequences appear to have therapeutic importance for prevention of H. pylori adhesion, as well as reduction of both inflammation and gastric mucosal injuries.
AN 2004:936243 HCAPLUS <<LOGINID::20100430>>
DN 142:148329
TI Glycoconjugates with NeuAc-NeuAc-Gal-Glc are more effective at preventing adhesion of Helicobacter pylori to gastric epithelial cells than glycoconjugates with NeuAc-Gal-Glc
AU Hata, Y.; Murakami, M.; Okabe, S.
CS Department of Geriatric Medicine, Kyoto University, Kyoto, Japan
SO Journal of Physiology and Pharmacology (2004), 55(3), 607-625
CODEN: JPHPEI; ISSN: 0867-5910
PB Polish Physiological Society
DT Journal
LA English
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI 36Fusion proteins comprising CD1d complex, α2 microglobulin and antibody or fragment for targeting therapy of tumor, autoimmune disease, inflammation and infection
AB The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ss2-microglobulin mol., and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compds., in particular anti-tumor

and autoimmunity responses.
AN 2004:292071 HCAPLUS <<LOGINID::20100430>>
DN 140:320040
TI 36Fusion proteins comprising CD1d complex, α2 microglobulin and antibody or fragment for targeting therapy of tumor, autoimmune disease, inflammation and infection
IN Robert, Bruno; Donda, Alena; Cesson, Valerie; Mach, Jean-Pierre; Zauderer, Maurice
PA Vaccinex, Inc., USA
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029206	A2	20040408	WO 2003-US30238	20030926
	WO 2004029206	A3	20041007		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1413316	A1	20040428	EP 2002-405838	20020927
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CA 2502735	A1	20040408	CA 2003-2502735	20030926
	AU 2003275254	A1	20040419	AU 2003-275254	20030926
	EP 1551448	A2	20050713	EP 2003-759526	20030926
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	IN 2005KN00523	A	20060127	IN 2005-KN523	20050329
	US 20060269540	A1	20061130	US 2006-529221	20060630
	IN 2007KN02053	A	20080801	IN 2007-KN2053	20070606
PRAI	EP 2002-405838	A	20020927		
	WO 2003-US30238	W	20030926		
	IN 2005-KN523	A3	20050329		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Antibodies produced by host cells tolerant to fucose-N-acetylglucosamine 1→6 α binding structure-recognizing lectins
AB Disclosed is a process for producing an antibody composition with the use of cells tolerant to a lectin recognizing a sugar chain structure in which an α-bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose; and cells usable in this process. The antibodies exhibit enhanced antibody-dependent cytotoxicity. The host cells have lower or defective carbohydrate modification-related proteins such as (1) GDP-fucose synthesizing enzyme proteins, (2) fucose-N-acetylglucosamine 1→6 α-binding structure-modifying enzyme proteins, and (3) GDP-fucose to Golgi body-transporting proteins, e.g. α-1,6-fucosyltransferase. The genes of these carbohydrate-modifying

enzymes are destroyed by gene targeting, dominant neg. body introduction, mutation or mutagenesis, transcription and/or translation inhibition, and RNAi. Antibodies prepared by the method include human antibodies, humanized or chimeric antibodies, antibody fragments and IgGs. These antibodies are prepared for diagnosis, prevention and treatment of cancer, allergy, inflammation, autoimmune disease, circulation disease, viral infection and bacterial infection.

AN 2003:818543 HCAPLUS <<LOGINID::20100430>>

DN 139:322290

TI Antibodies produced by host cells tolerant to fucose-N-acetylglucosamine 1→6 α binding structure-recognizing lectins

IN Satoh, Mitsuo; Kamachi, Reiko; Kanda, Yutaka; Mori, Katsuhiro; Yamano, Kazuya; Kinoshita, Satoko; Iida, Shigeru

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 297 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003085118	A1	20031016	WO 2003-JP4502	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481837	A1	20031016	CA 2003-2481837	20030409
	AU 2003236015	A1	20031020	AU 2003-236015	20030409
	US 20040132140	A1	20040708	US 2003-409616	20030409
	EP 1498490	A1	20050119	EP 2003-723096	20030409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-106820	A	20020409		
	JP 2003-24685	A	20030131		
	WO 2003-JP4502	W	20030409		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Antibodies produced by cells tolerant to lectin recognizing 1→6 α-bond between N-acetylglucosamine and fucose for diagnosis and therapy in patients suffering from FcγRIIIa polymorphism

AB A drug containing, as the active ingredient, an antibody composition produced with the use of cells tolerant to a lectin recognizing a sugar chain structure in which an α-bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose. This drug is appropriate for patients suffering from FcγRIIIa polymorphism who cannot be treated with a drug containing, as the active ingredient, an antibody composition produced from cells not tolerant to a lectin recognizing a sugar chain structure in which an α-bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside

bond-type complex sugar chain and the 1-position of fucose. Such chimeric antibodies specific to GD3, FGF8, CD20, and CCR4 were prepared for diagnosis, prevention and treatment of tumor, allergy, inflammation, autoimmune disease, circulation disorder, viral infection and bacterial infection.

AN 2003:818312 HCAPLUS <<LOGINID::20100430>>

DN 139:322285

TI Antibodies produced by cells tolerant to lectin recognizing 1→6 α-bond between N-acetylglucosamine and fucose for diagnosis and therapy in patients suffering from FcγRIIIa polymorphism

IN Nakamura, Kazuyasu; Shitara, Kenya; Hatanaka, Shigeki; Niwa, Rinpei; Okazaki, Akira

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 214 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084570	A1	20031016	WO 2003-JP4505	20030409
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2481925	A1	20031016	CA 2003-2481925	20030409
	AU 2003236019	A1	20031020	AU 2003-236019	20030409
	EP 1502603	A1	20050202	EP 2003-723099	20030409
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20050031613	A1	20050210	US 2003-409608	20030409
PRAI	JP 2002-106951	A	20020409		
	WO 2003-JP4505	W	20030409		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Isolation and identification of buffalo milk gangliosides and their use for humanization of infant and other formulas

AB The present invention relates to gangliosides derived or isolated from buffalo milk, skimmed buffalo milk, buffalo milk serum or derivs. of either. Buffalo milk is reported to comprise gangliosides that are not contained in bovine milk, such as gangliosides that belong to the GM1-class. Furthermore, buffalo milk is found to comprise unknown gangliosides, denoted herein as ganglioside "F" and "L". Furthermore, the invention reports that gangliosides are surprisingly found in fractions of isolation procedures that were so far not considered to comprise gangliosides. Finally, milk or milk serum from buffalo, for example as derived from mozzarella cheese production, contains specific gangliosides in the same amts. as human breast milk, which makes it suitable for humanization of infant and other formulas. Anti-inflammatory effects of buffalo milk gangliosides are also disclosed.

AN 2003:509876 HCAPLUS <<LOGINID::20100430>>

DN 139:68312

TI Isolation and identification of buffalo milk gangliosides and their use for humanization of infant and other formulas
IN Colarow, Ladislas; Turini, Marco; Berger, Alvin
PA Societe des Produits Nestle S.A., Switz.
SO Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1323424	A1	20030702	EP 2001-130614	20011227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003055497	A1	20030710	WO 2002-EP14876	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002361244	A1	20030715	AU 2002-361244	20021220
AU 2002361244	B2	20080807		
EP 1461048	A1	20040929	EP 2002-796763	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
NZ 534132	A	20061222	NZ 2002-534132	20021220
US 20050107311	A1	20050519	US 2004-498946	20040615
PRAI EP 2001-130614	A	20011227		
WO 2002-EP14876	W	20021220		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Inducing tolerance or immunomodulation using dendritic cells incubated with antigen
AB Disclosed is a method of altering immune responses using dendritic cells. One form of the method is a method of inducing immunol. tolerance in an individual, where type 2 dendritic cells are administered to an individual, and where the dendritic cells have been incubated with one or more antigens. Another form of the method involves altering an immune response, in which liposomes containing one or more antigens are administered to an individual, and where the liposomes are modified with surface-bound mols. that target the liposomes to type 2 dendritic cells. Another form of the method involves reducing immune responsiveness, where liposomes containing one or more antigens are administered to an individual and where the liposomes are modified with the surface bound mols. that target the liposomes to type 1 dendritic cells or type 2 dendritic cells. Another form of the method is a method of enhancing immune responsiveness, where liposomes containing one or more antigens are administered to an individual, and where the liposomes are modified with surface-bound mols. that target the liposomes to mature type 1 dendritic cells. The antigens can be autoantigens, alloantigens, tumor antigens, and viral antigens, and can be in the form of carbohydrates, peptides, nucleic acids, and lipids. The liposome surface-bound mols. can be specific for CD11c+ and/or BDCA-1,

which targets mature type 1 dendritic cells. Type 2 dendritic cells can be targeted by using surface-bound mols. specific for CD123, BDCA-2, and/or BDCA-4.

AN 2002:869052 HCAPLUS <<LOGINID::20100430>>
DN 137:336727
TI Inducing tolerance or immunomodulation using dendritic cells incubated with antigen
IN Waller, Edmund K.; Rosenthal, Hillary S.; Lonail, Sagar
PA Emory University, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090510	A2	20021114	WO 2002-US14497	20020508
	WO 2002090510	A3	20030410		
	WO 2002090510	A9	20040429		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002305452	A1	20021118	AU 2002-305452	20020508
	US 20050013810	A1	20050120	US 2004-477012	20040430
PRAI	US 2001-289625P	P	20010508		
	WO 2002-US14497	W	20020508		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Colostrum-based pharmaceutical compositions
AB A composition including colostrum or a colostrum-derived product and hyperimmune milk (HIM) or a hyperimmune milk-derived product, in amts. sufficient to provide a combined spectrum of pathogen-binding activity against a broad-spectrum of pathogenic organisms is described. For example, a test composition was prepared including 70% colostrum milk protein powder, 24% hyperimmune milk powder, 4% ganglioside-containing component, whey powder, lactose and 1.5% milk calcium. The test composition of the invention includes a combination of ingredients each of which has particular antimicrobial binding and/or anti-inflammatory activity which may combine to produce particular and unexpected clin. benefits in a broad range of diseases, including infection-associated diseases, and particularly gastrointestinal, inflammatory and bone related disorders. Such benefits are an unexpected result of the combination used.
AN 2002:391563 HCAPLUS <<LOGINID::20100430>>
DN 136:391021
TI Colostrum-based pharmaceutical compositions
IN Williams, Charles Edward; Hobman, Peter Graeme; Yarrow, Simon Stephen
PA Fonterra Co-Operative Group Limited, N. Z.
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2002040051	A1	20020523	WO 2001-NZ256	20011115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002024240	A	20020527	AU 2002-24240	20011115
	EP 1341554	A1	20030910	EP 2001-996393	20011115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004517067	T	20040610	JP 2002-542423	20011115
	HU 2004000589	A2	20040628	HU 2004-589	20011115
	HU 2004000589	A3	20050628		
	CN 1299771	C	20070214	CN 2001-822044	20011115
	US 20040047856	A1	20040311	US 2003-416831	20031008
	US 20050220894	A1	20051006	US 2005-136575	20050525
PRAI	NZ 2000-508234	A	20001115		
	WO 2001-NZ256	W	20011115		
	US 2003-416831	A3	20031008		

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Novel synthetic gangliosides
GI



I

AB Disclosed are novel synthetic ganglioside comprising a modified sphingosine group represented by Structural Formula (I); Y is -O- or -NH-; X is =O or -H2; R1 and R2 are independently a substituted or unsubstituted straight chain or branched hydrocarbyl group, wherein the hydrocarbyl group optionally comprises -S-, -S(O)-, -SO2-, -O- or -NR- (each R is independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group); and R3 is -H, -S(O)2H, -P(O)2OH, -N(O)OH or -P(O)2OP(O2)OH. Also disclosed are methods of treating a subject with a neurol. condition or disease and methods of treating a subject in need of immunosuppression. The subject can be, e.g., in need of neuroprotection, in need of neurogenesis, or in need of neuritogenesis. The method can be used for immunosuppression, e.g., a subject with organ, bone marrow, or stem cell transplant or a subject with autoimmune disease. The methods comprises the step of administering to the subject an effective amount of the synthetic ganglioside represented by Structural Formula (I).

AN 2002:171915 HCAPLUS <<LOGINID::20100430>>
DN 136:210593
TI Novel synthetic gangliosides
IN Ho, Tony W.
PA Neuronyx, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018401	A2	20020307	WO 2001-US27087	20010830
	WO 2002018401	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001085359	A	20020313	AU 2001-85359	20010830
PRAI	US 2000-654363	A1	20000901		
	WO 2001-US27087	W	20010830		

OS MARPAT 136:210593
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immunotherapies
AB The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as an anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant Ig polypeptide chain sufficient to elicit a cytokine-specific biol. response.
AN 2000:573686 HCAPLUS <<LOGINID::20100430>>
DN 133:176175
TI Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immunotherapies
IN Lode, Holger N.; Reisfeld, Ralph A.; Cheresh, David A.; Gillies, Stephen D.
PA The Scripps Research Institute, USA; Lexigen Pharmaceuticals Corporation
SO PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047228	A1	20000817	WO 2000-US3483	20000211
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

```
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
            DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
            CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2360106           A1    20000817    CA 2000-2360106        20000211
     AU 2000032280        A     20000829    AU 2000-32280          20000211
     AU 776790            B2    20040923
     EP 1156823           A1    20011128    EP 2000-910138         20000211
     EP 1156823           B1    20081029
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, AL, MK
     BR 2000008161        A     20020528    BR 2000-8161           20000211
     HU 2002000128        A2    20020529    HU 2002-128            20000211
     JP 2002536419        T     20021029    JP 2000-598179         20000211
     RU 2236251           C2    20040920    RU 2001-124907         20000211
     CN 1192796           C     20050316    CN 2000-806134         20000211
     US 7115261           B1    20061003    US 2000-502732         20000211
     AT 412433            T     20081115    AT 2000-910138         20000211
     PT 1156823           E     20090108    PT 2000-910138         20000211
     ES 2313883           T3    20090316    ES 2000-910138         20000211
     ZA 2001006455        A     20021106    ZA 2001-6455           20010806
     NO 2001003906        A     20011009    NO 2001-3906           20010810
     MX 2001008110        A     20021023    MX 2001-8110           20010810
     US 20070036751       A1    20070215    US 2006-527029         20060926
     US 7365054           B2    20080429
     US 20090060864       A1    20090305    US 2008-148629         20080421
PRAI US 1999-119721P      P     19990212
     US 2000-502732       A3    20000211
     WO 2000-US3483       W     20000211
     US 2006-527029       A3    20060926
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s cholesterol or hypercholesterolem? or atherosclerosis
        211313 CHOLESTEROL
         20859 HYPERCHOLESTEROLEM?
         72634 ATHEROSCLEROSIS
L5      265180 CHOLESTEROL OR HYPERCHOLESTEROLEM? OR ATHEROSCLEROSIS

=> s l2 and l5
L6           8 L2 AND L5

=> d l6 1-8 ti abs bib

L6   ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Method and apparatus of low strength electric field network-mediated
     delivery of drug, gene, siRNA, shRNA, protein, peptide, antibody or other
     biomedical and therapeutic molecules and reagents in skin, soft tissue,
     joints and bone
AB   The invention includes four preferred embodiments: (i) a method and apparatus
     for the joint and its related soft tissue for bone gene, protein and drug
     delivery; (ii) a method and apparatus for gene, protein and drug delivery to an
     extremity; (iii) a method and apparatus for delivery of gene, protein and drug
     delivery to skin and soft tissue; and/or (iv) a method and apparatus for
     delivery of a gene, protein and drug to soft tissue tumor.  The apparatus for
     transfecting drug, gene, siRNA, shRNA, protein, peptide, antibody or other
     biomedical and therapeutic mols. and reagents comprises a plurality of
     neg. electrodes disposed into low resistance elec. contact with skin
     overlaying the tissue.
```

AN 2007:1207931 HCAPLUS <<LOGINID::20100430>>
DN 147:474740
TI Method and apparatus of low strength electric field network-mediated delivery of drug, gene, siRNA, shRNA, protein, peptide, antibody or other biomedical and therapeutic molecules and reagents in skin, soft tissue, joints and bone
IN Sen, Luyi
PA The University of California, USA
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007120557	A2	20071025	WO 2007-US8445	20070402
	WO 2007120557	A3	20081113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	CA 2647520	A1	20071025	CA 2007-2647520	20070402
	EP 2001519	A2	20081217	EP 2007-774731	20070402
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	CN 101506370	A	20090812	CN 2007-80000069	20070830
	IN 2008CN05422	A	20090320	IN 2008-CN5422	20081010
PRAI	US 2006-744528P	P	20060410		
	US 2006-819277P	P	20060706		
	WO 2007-US8445	W	20070402		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Formulations for mediating inflammatory bowel disorders
AB The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liqs. with gangliosides, for example infant formula or infant foods, can be employed according to the invention.
AN 2007:815148 HCAPLUS <<LOGINID::20100430>>
DN 147:197354
TI Formulations for mediating inflammatory bowel disorders
IN Clandinin, Michael Thomas; Park, Eek J.
PA Mti Meta Tech Inc., Can.
SO U.S. Pat. Appl. Publ., 39pp., Cont.-in-part of U.S. Ser. No. 551,789
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070173480	A1	20070726	US 2007-622858	20070112
	WO 2004087173	A2	20041014	WO 2004-CA375	20040312
	WO 2004087173	A3	20041125		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20060276430	A1	20061207	US 2004-551789	20040312
PRAI	US 2004-551789	A2	20040312		
	WO 2004-CA375	W	20040312		
	US 2003-404095	A	20030402		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L6 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Anti-atherosclerotic mechanisms of ganglioside GD3, antioxidant PDTC and flavonoid quercetin in vascular smooth muscle cells

AB A review. Sialic acid containing glycosphingolipids (gangliosides) have been implicated in regulating various biol. phenomena such as atherosclerosis. Disialoganglioside (GD3) inhibited DNA synthesis of cultured VSMC in the presence of PDGF with down-regulation of cyclinE/CDK2 and up-regulation of the CDK inhibitor p21 and p27 expression. GD3 inhibited TNF-α-induced matrix metalloproteinase-9 (MMP-9) expression in VSMC and decreased MMP-9 promoter activity in response to TNF-α, which was transcriptionally regulated at NF-κB and activation protein-1 (AP-1) sites in the MMP-9 promoter. These suggest that the GD3 represents a physiol. modulator of VSMC responses that may contribute to plaque instability in atherosclerosis. On the other hand, pyrrolidine dithiocarbamate (PDTC), a metal chelating antioxidant and pro-oxidant compound reduced cell growth and DNA synthesis on VSMC in low d. conditions. However, in serum depleted medium, PDTC did not affect the cell viability. At low VSMC d. in 10% FBS, PDTC induced cell cycle arrest in the G1 phase. The cell cycle arrest is associated with the down-regulation of cyclin D1, cyclin E, CDK2, CDK4 and up-regulation of the CDK inhibitor p21 expression. These inhibitory effects were associated with enhanced expression of p21 and increased complexing of p21 with cyclin D1/CDK4 and cyclin E/CDK2. PDTC induced marked activation of p38MAPK and JNK. SB203580, a p38MAPK specific inhibitor, blocked PDTC-dependent p38MAPK, growth inhibition, and p21 expression. The cells were transfected with antisense-p21 oligodeoxynucleotide also decreased PDTC-induced p38 MAPK activity. These data demonstrate that the p38MAPK pathway participates in p21 induction, leading to decrease of cyclin D1/cdk4 and cyclin E/cdk2 complexes and PDTC-dependent VSMC growth inhibition. Finally, quercetin, a bioflavonoid, is known to inhibit angiotensin II-induced hypertrophy and serum-induced smooth muscle cell proliferation. Treatment of quercetin showed potent inhibitory effects on DNA synthesis of cultured human aortic smooth muscle cells (HASMC) in the presence of TNF-α. These inhibitory effects were associated with reduced extracellular signal-regulated kinase (ERK) 1/2 activity and G1 cell cycle arrest.

Quercetin induced down-regulation of cyclins and CDKs and up-regulation of the CDK inhibitor p21 expression. Quercetin inhibited TNF-α-induced MMP-9 secretion on HASMC in a dose dependent manner by down-regulation of MMP-9, indicating the efficacy of quercetin in inhibiting cell proliferation, G1 to S phase cell cycle progress and MMP-9 expression through the transcription factors NF-kB and AP-1 on TNF-α-induced HASMC.

AN 2007:413849 HCAPLUS <<LOGINID::20100430>>
DN 146:513511
TI Anti-atherosclerotic mechanisms of ganglioside GD3, antioxidant PDTC and flavonoid quercetin in vascular smooth muscle cells
AU Kim, Cheorl-Ho; Jin, Un-Ho; Suh, Seok-Jong; Moon, Sung-Kwon
CS National Research Laboratory for Glycobiology, Korean Ministry of Science and Technology, Kyungju, 780-714, S. Korea
SO Current Topics in Biotechnology (2005), 2, 93-113
CODEN: CTBUAI; ISSN: 0972-821X
PB Research Trends
DT Journal; General Review
LA English
RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Methods of cancer treatment/prevention using cancer cell-specific surface antigens
AB The authors disclose the elicitation of specific cellular and humoral immune responses against cancer cell surface antigens, including those cancer cell surface antigens expressed only in cancer cells and in non-cancer cells normally located in one or more immune-privileged sites or tissues of the individual. The method comprises using specifically prepared immunogen in fresh or lyophilized liposomes, proper routes of administration of the immunogen, proper doses of the immunogen, and specific combinations of heterologous immunization including DNA priming followed by liposomal protein boost to tailor the immune responses. In one example, the authors employ liposomal HBsAg as a model cancer antigen.
AN 2006:438034 HCAPLUS <<LOGINID::20100430>>
DN 144:449376
TI Methods of cancer treatment/prevention using cancer cell-specific surface antigens
IN Kislauskis, Edward; Yang, Kejian; Whalen, Barbara J.
PA Biomedical Research Models, Inc., USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006050116	A1	20060511	WO 2005-US38968	20051027

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

```
     EP 1812052           A1    20070801    EP 2005-819700         20051027
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
     US 20080267963       A1    20081030    US 2008-666956         20080521
PRAI US 2004-624296P      P     20041102
     WO 2005-US38968      W     20051027
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6   ANSWER 5 OF 8  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Antibodies conjugated with phagocytic marker for enhancing phagocytosis
     against autoimmune disease, infection, cancer and others
AB   The present invention provides a system for enhancing clearance or
     destruction of undesirable cells or noncellular mol. entities by tagging
     such cells or noncellular mol. entities with a marker that targets the
     cells or noncellular mol. entities for phagocytosis (phagocytic marker).
     The target cells can be, for example, endothelial cells, tumor cells,
     leukocytes, or virus-infected cells.  In certain embodiments of the
     invention the tagging is accomplished by administering a composition comprising
     an antibody or ligand linked to the phagocytotic marker, wherein the
     antibody or ligand binds to a cell type specific marker present on or in
     the cell surface of a target cell.  In preferred embodiments of the
     invention, the phagocytic marker comprises phosphatidylserine or a group
     derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative
     of any of these.
AN   2005:182810  HCAPLUS <<LOGINID::20100430>>
DN   142:278750
TI   Antibodies conjugated with phagocytic marker for enhancing phagocytosis
     against autoimmune disease, infection, cancer and others
IN   Francois, Cedric; Olson, Paul; Deschatelets, Pascal; Machiels, Alec
PA   Potentia Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 173 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
PI   WO 2005019429         A2    20050303    WO 2004-US27245        20040823
     WO 2005019429         A3    20060302
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 20050113297       A1    20050526    US 2004-923940         20040823
PRAI US 2003-497086P      P     20030822
     US 2003-514941P      P     20031028
     US 2003-523611P      P     20031119
     US 2003-524126P      P     20031121
     US 2003-524730P      P     20031124
     US 2004-547951P      P     20040226
     WO 2004-US27245      A     20040823
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 142:278750
```

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Potentiation of immune responses with liposomal adjuvants
AB A high-integrity liposome comprising at least one stable lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use are disclosed. Immunizing dosage forms comprising a liposome and an immunogen, wherein said liposome and immunogen are present in an immunization dose are provided. Addnl., a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen wherein said organic acid derivative of a sterol and immunogen are present in an immunization dose, and method according to use is disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristoylphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein said DMPC/cholesterol and immunogen are present in an immunization dose, and method according to use is presented.
AN 2000:492029 HCAPLUS <<LOGINID::20100430>>
DN 133:109954
TI Potentiation of immune responses with liposomal adjuvants
IN Popescu, Mircea C.; Weiner, Alan L.; Recine, Marie S.; Janoff, Andrew S.; Estis, Leonard; Keyes, Lynn D.; Alving, Carl R.
PA The Liposome Company, Inc., USA
SO U.S., 23 pp., Cont.-in-part of U.S. 5,231,112.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6090406	A	20000718	US 1990-485388	19900226
	US 4721612	A	19880126	US 1985-721630	19850410
	JP 09040550	A	19970210	JP 1996-191707	19850411
	US 4891208	A	19900102	US 1985-773429	19850910
	ZA 8507576	A	19860625	ZA 1985-7576	19851001
	IL 96444	A	19921201	IL 1985-96444	19851006
	DD 255533	A5	19880406	DD 1985-281616	19851010
	AU 8775438	A	19880111	AU 1987-75438	19870612
	JP 01501622	T	19890608	JP 1987-503771	19870612
	CA 1337898	C	19960109	CA 1988-584808	19881202
	US 6759057	B1	20040706	US 1989-323182	19890313
	AU 8941861	A	19900323	AU 1989-41861	19890824
	AU 627226	B2	19920820		
	AU 8942214	A	19900323	AU 1989-42214	19890824
	AU 631377	B2	19921126		
	JP 04500203	T	19920116	JP 1989-509162	19890824
	CA 1334165	C	19950131	CA 1989-609463	19890825
	US 5231112	A	19930727	US 1989-425727	19891023
	JP 07100367	A	19950418	JP 1993-268664	19931027
	JP 2568034	B2	19961225		
	US 5897873	A	19990427	US 1995-392676	19950223
PRAI	US 1984-599691	B2	19840412		
	US 1985-721630	A2	19850410		
	US 1985-773429	A2	19850910		
	US 1986-873584	B2	19860612		
	US 1986-934151	B2	19861124		

US 1987-61186	B2	19870611
US 1987-128974	B2	19871204
US 1988-236701	B2	19880825
US 1988-236702	B2	19880825
US 1988-277854	B2	19881130
US 1989-397777	B2	19890823
US 1989-425727	A2	19891023
JP 1985-502090		19850411
JP 1993-268664	A3	19850411
IL 1985-76600	A3	19851006
WO 1987-US1402	A	19870612
US 1989-397758	A	19890823
WO 1989-US3657	A	19890824
WO 1989-US3658	A	19890824
US 1991-758587	A1	19910912
US 1993-108822	A2	19930818
US 1993-146463	B1	19931102

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 41 THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (47 CITINGS)
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
AB A high integrity liposome comprising at least one stable lipid and at least one peptide-like therapeutic agent associated with the liposome, adapted for parenteral administration to an animal, including a human, and a method for manufacture and use are disclosed. Immunizing dosage forms comprise a liposome and an immunogen, wherein the liposome and immunogen are present in an immunization dose. Addnl., a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen present in an immunization dose, and a method for use are disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristolyphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein the DMPC/cholesterol and immunogen are present in an immunization dose, and method for their use are disclosed.
AN 1999:412601 HCAPLUS <<LOGINID::20100430>>
DN 131:63430
TI Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
IN Popescu, Mircea C.; Weiner, Alan L.; Recine, Marie S.; Janoff, Andrew S.; Estis, Leonard; Keyes, Lynn D.; Alving, Carl R.
PA The Liposome Company, Inc., USA
SO U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 108,822.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5916588	A	19990629	US 1995-452549	19950525
US 4721612	A	19880126	US 1985-721630	19850410
JP 09040550	A	19970210	JP 1996-191707	19850411
US 4891208	A	19900102	US 1985-773429	19850910
ZA 8507576	A	19860625	ZA 1985-7576	19851001
IL 96444	A	19921201	IL 1985-96444	19851006
DD 255533	A5	19880406	DD 1985-281616	19851010

	AU 8775438	A	19880111	AU 1987-75438	19870612
	JP 01501622	T	19890608	JP 1987-503771	19870612
	CA 1337898	C	19960109	CA 1988-584808	19881202
	US 6759057	B1	20040706	US 1989-323182	19890313
	AU 8941861	A	19900323	AU 1989-41861	19890824
	AU 627226	B2	19920820		
	AU 8942214	A	19900323	AU 1989-42214	19890824
	AU 631377	B2	19921126		
	JP 04500203	T	19920116	JP 1989-509162	19890824
	CA 1334165	C	19950131	CA 1989-609463	19890825
	US 5231112	A	19930727	US 1989-425727	19891023
	US 5288499	A	19940222	US 1991-758587	19910912
	US 6352716	B1	20020305	US 1993-108822	19930818
	JP 07100367	A	19950418	JP 1993-268664	19931027
	JP 2568034	B2	19961225		
	US 5897873	A	19990427	US 1995-392676	19950223
PRAI	US 1984-599691	B2	19840412		
	US 1985-721630	A2	19850410		
	US 1985-773429	A2	19850910		
	US 1986-873584	B2	19860612		
	US 1986-934151	A2	19861124		
	US 1987-61186	B2	19870611		
	US 1987-128974	B2	19871204		
	US 1988-236701	A2	19880825		
	US 1988-236702	B2	19880825		
	US 1988-277854	B2	19881130		
	US 1989-397777	B2	19890823		
	US 1989-425727	A3	19891023		
	US 1991-758587	A1	19910912		
	US 1993-108822	A2	19930818		
	JP 1985-502090		19850411		
	JP 1993-268664	A3	19850411		
	IL 1985-76600	A3	19851006		
	WO 1987-US1402	A	19870612		
	US 1989-397758	A	19890823		
	WO 1989-US3657	A	19890824		
	WO 1989-US3658	A	19890824		
	US 1993-146463	B1	19931102		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Ganglioside immunostimulating complexes and uses thereof
AB The present invention relates generally to an immunostimulating complex comprising one or more gangliosides and more particularly to an immunostimulating complex comprising at least one of the gangliosides GM2, GD2, GD3 or GT3. The immunogenic immunostimulating complex also comprises a saponin preparation, a sterol, a protein epitope, and phospholipid. The protein may be cancer specific protein, melanoma specific protein, or influenza hemagglutinin. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent in the treatment of tumors, and more particularly, melanomas.
AN 1999:7859 HCAPLUS <<LOGINID::20100430>>
DN 130:65237
TI Ganglioside immunostimulating complexes and uses thereof
IN Cox, John Cooper; Ronnberg, Bengt John Lennart; Sjolander, Sigrid Elisabet
PA Eriksson, Lennart, Australia; CSL Limited
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9856420	A1	19981217	WO 1998-AU453	19980612
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2293439	A1	19981217	CA 1998-2293439	19980612
	AU 9880035	A	19981230	AU 1998-80035	19980612
	AU 725342	B2	20001012		
	ZA 9805140	A	19990107	ZA 1998-5140	19980612
	EP 1019087	A1	20000719	EP 1998-928010	19980612
	EP 1019087	B1	20071121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	NZ 501641	A	20001222	NZ 1998-501641	19980612
	JP 2002504101	T	20020205	JP 1999-501150	19980612
	US 6814981	B1	20041109	US 2000-445749	20000210
	HK 1026855	A1	20080606	HK 2000-106085	20000926
PRAI	AU 1997-7329	A	19970612		
	WO 1998-AU453	W	19980612		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT